8IYX image
Entry Detail
PDB ID:
8IYX
EMDB ID:
Title:
Cryo-EM structure of the GPR34 receptor in complex with the antagonist YL-365
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-04-06
Release Date:
2024-03-20
Method Details:
Experimental Method:
Resolution:
3.34 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Probable G-protein coupled receptor 34,Probable G-protein coupled receptor 34,YL-365
Chain IDs:A (auth: C)
Chain Length:581
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Cryo-EM structures of human GPR34 enable the identification of selective antagonists.
Proc.Natl.Acad.Sci.USA 120 e2308435120 e2308435120 (2023)
PMID: 37733739 DOI: 10.1073/pnas.2308435120

Abstact

GPR34 is a functional G-protein-coupled receptor of Lysophosphatidylserine (LysoPS), and has pathogenic roles in numerous diseases, yet remains poorly targeted. We herein report a cryo-electron microscopy (cryo-EM) structure of GPR34 bound with LysoPS (18:1) and Gi protein, revealing a unique ligand recognition mode with the negatively charged head group of LysoPS occupying a polar cavity formed by TM3, 6 and 7, and the hydrophobic tail of LysoPS residing in a lateral open hydrophobic groove formed by TM3-5. Virtual screening and subsequent structural optimization led to the identification of a highly potent and selective antagonist (YL-365). Design of fusion proteins allowed successful determination of the challenging cryo-EM structure of the inactive GPR34 complexed with YL-365, which revealed the competitive binding of YL-365 in a portion of the orthosteric binding pocket of GPR34 and the antagonist-binding-induced allostery in the receptor, implicating the inhibition mechanism of YL-365. Moreover, YL-365 displayed excellent activity in a neuropathic pain model without obvious toxicity. Collectively, this study offers mechanistic insights into the endogenous agonist recognition and antagonist inhibition of GPR34, and provides proof of concept that targeting GPR34 represents a promising strategy for disease treatment.

Legend

Protein

Chemical

Disease

Primary Citation of related structures